{"disease":{"id":"acquired-pure-red-cell-aplasia","name":"acquired pure red cell aplasia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06412497","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT04423367","title":"Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07031115","title":"Linperlisib in the Treatment of aPRCA","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}